All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Bookmark this article
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Peter van de Kerkhof, Radboud University, Nijmegen, NL. We asked, What’s on the horizon for the treatment of psoriasis?
What’s on the horizon for the treatment of psoriasis?
After briefly reviewing the history of psoriasis treatment, with a slide on the key signaling pathways, van der Kerkof discusses novel treatments for psoriasis, such as deucravacitinib, apremilast, and tapinarof. Next, the changing perspectives on the classification of psoriasis as a skin disease or a systemic condition are considered. To read more about the classification of psoriasis, please see our article "An overview of the epidemiology diagnosis classification and management of psoriasis" that be found here: https://psoriasis-hub.com/medical-information/an-overview-of-the-epidemiology-diagnosis-classification-and-management-of-psoriasis
At ACR 2022, Phillip Mease reported data from a phase II trial of deucravacitinib in patients with psoriatic arthritis, with a focus on Part B of the trial, which involved treatment up to Week...
During the 31st EADV Congress, Mark Lebwohl presented the long-term efficacy results of deucravacitinib and Diamant Thaçi presented on...
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox